Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke.

ABSTRACT:

Purpose of review

To review the current evidence and ongoing clinical trials evaluating the efficacy and safety of tenecteplase (TNK), an alternative tissue plasminogen activator (tPA), in the acute management of arterial ischemic stroke (AIS). To date, alteplase is the only tPA approved by the United States FDA for use in AIS.

Recent findings

There have been multiple phase two and three trials investigating the safety and efficacy of TNK in AIS. In patients with AIS due to large vessel occlusion, one randomized controlled trial demonstrated superiority of TNK for vessel recanalization rates and long-term functional outcomes when compared to alteplase. A meta-analysis of all phase two and three trials evaluating TNK in AIS concluded that TNK has a comparable safety and effic

SUBMITTER: Alhadid K 

PROVIDER: S-EPMC9807245 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature